Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials
Johnson et al -2001 (view as PDF)...
Call:
+44 (0) 1865 784074
Oxford Vacmedix UK Limited:
Oxford, UK, OX4 4GA
Email:
enquiries@oxfordvacmedix.com
- Seeking Series B investment for next phase of clinical trials
Call:
+44 (0) 1865 784074
Oxford Vacmedix UK Limited:
Oxford, UK, OX4 4GA
Email:
enquiries@oxfordvacmedix.com
News & Articles
Expression and clinical significance of survivin in ovarian cancer: A meta-analysis
He et al – 2018 (view as PDF)...
Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines
Guidance for Industry, Clinical Considerations for Therapeutic Cancer Vaccines (view as PDF)...
Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma
Fenstermaker et al – 2016 (view as PDF)...
Protective cellular immunity generated by cross-presenting recombinant overlapping peptide proteins
Cai et al -2017 (view as PDF)...
Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients
Berinstein et al – 2015 (view as PDF)...
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
Ambrosini, Adida and Altieri -1997 (view as PDF)...
Contact Us
If you have any questions or want to get in touch, please contact our team.
(c) 2025 Oxford Vacmedix UK Limited | Company Registration: 07994205
English